Vanda Pharma (VNDA) Tops by 3c, Posts Q3 Loss of $0.28
More News related to VNDA
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010
- Novartis (NVS) Launches Vanda Pharma's (VNDA) Fanapt Schizophrenia Treatment
- Fanapt(TM) Launches in the U.S.
- Jefferies Starts Vanda Pharma (VNDA) at Buy
- Vanda Pharma (VNDA) to Receive $200M from Novartis (NVS) Upon Expiration of HSR Antitrust Improvements Act
More News related to Earnings
- Forrester Research (FORR) Posts Q4 EPS of $0.35 Tops by 7c; Guides Q110 and FY10
- NetSol (NTWK) Reports Q2 Loss of $0.01, Misses by 2c; Reaffirms Guidance
- Rentech (RTK) Reports Q1 Loss of $0.07
- Textainer (TGH) Tops Q4 Earnings Views
- Sprint Nextel (S) Q4 Losses Narrow, But Miss Expectations
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reports Q3 loss of $0.28, 3 cents better than the analyst estimate of ($0.31).
Related Categories
EarningsStocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
